CA
NZ
UK
AU
IND
US
…
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Dermata Therapeutics Inc is a clinical-stage dermatology company developing topical therapeutics for inflammatory and rare skin conditions. Its long-term growth could be driven by clinical trial results, regulatory approvals, licensing partnerships and eventual commercial execution. Investors may find the company attractive because successful late-stage data and approvals could unlock high-margin specialty dermatology markets.
Principal risks include clinical and regulatory failure, limited operating history and funding needs, competitive pressures and potential commercialization challenges; investors should monitor trial outcomes, cash runway and partnering progress.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -7.56M | -12.29M | -7.79M | -9.61M | -7.90M |
| Net income | -7.56M | -12.29M | -7.79M | -9.61M | -7.95M |
| Selling general administrative | 4.84M | 4.31M | 3.97M | 4.02M | 4.40M |
| Selling and marketing expenses | - | - | 3968.17M | - | - |
| Reconciled depreciation | - | - | - | - | 0.00M |
| Ebit | - | -24.80M | -7.79M | -9.67M | -7.86M |
| Ebitda | -7.77M | -12.29M | 0.25M | -9.67M | -7.86M |
| Depreciation and amortization | - | 12.51M | 8.04M | - | 0.01M |
| Operating income | -7.77M | -12.51M | -8.04M | -9.67M | -7.86M |
| Other operating expenses | 7.77M | 12.51M | 8.04M | 9.67M | 7.86M |
| Interest expense | - | - | - | 0.06M | 0.05M |
| Interest income | 0.22M | 0.23M | 0.25M | - | - |
| Net interest income | 0.22M | 0.23M | 0.20M | 0.06M | -0.05M |
| Income tax expense | - | - | -0.01M | - | 0.05M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 7.77M | 12.51M | 8.04M | 9.67M | 7.86M |
| Total other income expense net | 0.22M | 0.23M | 0.25M | 0.06M | -0.05M |
| Net income from continuing ops | -7.56M | -12.29M | -7.33M | -9.61M | -7.90M |
| Net income applicable to common shares | - | - | - | -9.61M | -10.46M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 7863.83M | 3.53M | 7.98M | 6.94M | 11.62M |
| Other current assets | - | 0.37M | 0.53M | 0.69M | 0.83M |
| Total liab | 1640.45M | 1.97M | 1.62M | 0.92M | 1.52M |
| Total stockholder equity | 6223.38M | 1.56M | 6.36M | 6.02M | 10.11M |
| Other current liab | 1.18M | 1.16M | 0.76M | 0.43M | 1.00M |
| Common stock | 0.27M | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -73233.90M | -65.68M | -53.39M | -45.59M | -35.98M |
| Other assets | 341.85M | 372.32M | 540.50M | 703.19M | 825.13M |
| Cash | 7521.98M | 3.16M | 7.44M | 6.24M | 10.80M |
| Total current liabilities | 1.64M | 1.97M | 1.62M | 0.92M | 1.52M |
| Net debt | -7521.98M | -3.16M | -7.44M | -6.24M | -10.80M |
| Other stockholder equity | 79457.01M | 67.24M | 59.74M | 51.61M | 46.09M |
| Total current assets | 7521.98M | 3.53M | 7.98M | 6.94M | 11.62M |
| Net tangible assets | - | - | - | 6.02M | 10.11M |
| Short term investments | - | 3158.41M | - | - | - |
| Net receivables | - | - | 0.01M | 0.01M | - |
| Accounts payable | 0.46M | 0.81M | 0.87M | 0.50M | 0.52M |
| Accumulated other comprehensive income | - | 0.00M | - | - | - |
| Non current assets total | 0.00M | -3158.04M | 0.00M | 0.00M | 0.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Change to liabilities | - | - | - | -0.02M | 0.41M |
| Net borrowings | - | - | - | - | 1.01M |
| Total cash from financing activities | 12117.97M | 6.89M | 7.61M | 4.28M | 15.96M |
| Change to operating activities | - | - | - | -0.14M | -0.12M |
| Net income | -7558.56M | -12.29M | -7.79M | -9.61M | -7.90M |
| Change in cash | 4360.41M | -4.28M | 1.20M | -4.56M | 10.27M |
| Begin period cash flow | 3161.57M | 7.44M | 6.24M | 10.80M | 0.53M |
| End period cash flow | 7521.98M | 3.16M | 7.44M | 6.24M | 10.80M |
| Total cash from operating activities | -7757.56M | -11.16M | -6.41M | -8.83M | -5.69M |
| Issuance of capital stock | 12.17M | 6.89M | 5.65M | 4.28M | 15.96M |
| Depreciation | - | - | - | - | 0.01M |
| Dividends paid | - | - | - | - | 2.29M |
| Sale purchase of stock | -0.00M | -0.00M | -0.00M | 0.00M | -1.00M |
| Other cashflows from financing activities | 12105.85M | 0.00M | 0.00M | 0.00M | 2.13M |
| Change to netincome | - | - | - | 0.93M | 1.91M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | -0.34M | 0.47M | 0.86M | -0.15M | 0.29M |
| Stock based compensation | 143.73M | 0.66M | 0.52M | 0.93M | 1.91M |
| Other non cash items | -342.39M | -656.99M | 0.37M | - | 0.01M |
| Free cash flow | -7757.56M | -11.16M | -6.41M | -8.83M | -5.69M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| DRMA Dermata Therapeutics Inc |
0.04 5.39% |
0.82 | - | - | - | 0.86 | 0.58 |
| NVO Novo Nordisk A/S |
0.29 0.72% |
40.29 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
5.51 0.99% |
564.39 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
34.06 3.67% |
961.95 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
3525 Del Mar Heights Rd., San Diego, CA, United States, 92130
858 800 2543
9
| Name | Title | Year Born |
|---|---|---|
| Mr. Gerald T. Proehl | Founder, Pres, CEO & Chairman | 1959 |
| Mr. David F. Hale | Co-Founder & Lead Independent Director | 1949 |
| Ms. Kyri K. Van Hoose CPA, M.B.A. | Sr. VP & CFO | 1979 |
| Dr. Christopher J. Nardo M.P.H., Ph.D. | Sr. VP & Chief Devel. Officer | 1965 |
| Mr. Sean Proehl | Sr. Director of Legal & Bus. Devel. | NA |
| Dr. Maria Bedoya Toro Munera M.B.A., Ph.D. | Sr. VP of Regulatory Affairs & Quality Assurance | 1952 |
| Mr. Gerald T. Proehl | Founder, President, CEO & Chairman | 1959 |
| Ms. Kyri K. Van Hoose CPA, M.B.A. | Senior VP & CFO | 1978 |
| Dr. Christopher J. Nardo M.P.H., Ph.D. | Senior VP & Chief Development Officer | 1965 |
| Mr. Sean Proehl | Senior Director of Legal & Business Development | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.80%
Communication Services
+0.61%
Consumer Cyclical
+1.47%
Consumer Defensive
+0.78%
Energy
-1.20%
Financial Services
+0.87%
Financials
+0.88%
Healthcare
-0.33%
Industrials
+0.85%
Real Estate
+0.50%
Technology
+0.39%
Utilities
+0.03%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...